Novartis’ asciminib hasoutperformedPfizer’s Bosulif in a phase 3 chronic myeloid leukemia (CML) stud
READ MORE 2021-11-01News List
Novartis' asciminib bests Pfizer's Bosulif in phase 3 leukemia trial
Hengrui announces new drug SHR7280
On October 11, 2021, Jiangsu Hengrui Pharmaceuticals Co., Ltd. announced that SHR0302, for the treat
READ MORE 2021-10-15
FDA Grants Breakthrough Therapy Designation to Merck’s Novel HIF-2α Inhibitor MK-6482 for Treatment of Certain Patients With Von Hippel-Lindau Disease- Associated Renal Cell Carcinoma
Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the U.S.
READ MORE 2021-09-07
Novartis secures new approval in China for Cosentyx® (secukinumab) in pediatric psoriasis
August 17, 2021 – Novartis today announced that the China National Medical Products Administration (
READ MORE 2021-08-22
Bayer’s new symptomatic chronic heart failure treatment Verquvo™ (vericiguat) approved in EU
Berlin, Germany, July 21, 2021– The European Commission has granted marketing authorization in the E
READ MORE 2021-07-26
USFDA approves KIT inhibitor Ayvakit (Avatinib)
CStone's partner Blueprint Medicines recently announced that the U.S. Food and Drug Administrati
READ MORE 2021-06-24
AbbVie Presents New Late-Breaking Data Analyses Showing Risankizumab (SKYRIZI®) Achieves Clinical Remission and Endoscopic Response at Week 12 in Patients with Moderate to Severe Crohn's Disease
Late-breaking data analyses presented by AbbVie (NYSE: ABBV) at Digestive Disease Week®(DDW) Virtual
READ MORE 2021-06-01
Xofluza was approved in China
On April 29, 2021, Roche China announced that its innovative influenza drug Xofluza® (Mabaloxavir) h
READ MORE 2021-05-13
Tagrisso approved in China in early lung cancer
AstraZeneca'sTagrisso(osimertinib) has been approved in China for the adjuvant treatment of pati
READ MORE 2021-04-15
Gilead’s Investigational Lenacapavir Demonstrates Sustained Long-Acting Efficacy Through Week 26 in Data Presented at CROI
Gilead Sciences, Inc. (Nasdaq: GILD) today presented additional results from the Phase 2/3 CAPELLA t
READ MORE 2021-03-15